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Introduction: The clinical beneﬁts of remote monitoring (RM) of cardiac-implanted devices have not
been fully evaluated in Japan. We investigated the clinical beneﬁts of RM in a single center in Japan.
Methods: Patients with pacemakers, implantable cardioverter-deﬁbrillators (ICD), or cardiac resyn-
chronization therapy with deﬁbrillators (CRT-D) were assigned to RM and non-RM groups. The
outpatient wait times and times to notiﬁcation of EVENTS that we deﬁned sustained ventricular
tachyarrhythmias, worsening heart failure, and inappropriate therapy for supraventricular tachyar-
rhythmias in this study, were compared between the 2 groups.
Results: A total of 416 patients (RM: 61; non-RM: 355) were evaluated. The outpatient wait time was
17.6722.1 min for the RM group and 35.6725.2 min for the non-RM group (Po0.001). Seventy-seven
and 306 EVENTS were observed in 38 and 256 patients during mean follow-up periods of 360722 days
and 429710 days in the RM and non-RM groups, respectively. The times to notiﬁcation of EVENTS
were 8.1716.2 days for the RM group and 38.7733.2 days for the non-RM group (Po0.001).
Conclusions: RM signiﬁcantly shortened outpatient wait times and times to notiﬁcation of EVENTS.
Therefore, RM was clinically beneﬁcial in a single center in Japan.
& 2012 Japanese Heart Rhythm Society. Published by Elsevier B.V. All rights reserved.1. Introduction
Cardiac-implanted devices offer multiple programmable fea-
tures and can store large amounts of diagnostic information
related to the device function, arrhythmia frequency, hemody-
namic or physiologic parameters, and patient activity. Traditional
device follow-up requires direct interrogation of the device in
order to view the programmed parameters and stored diagnostic
data, identify and correct possible malfunctions, and optimize
therapy by reprogramming the device [1]. As the use of implanted
cardiac devices has expanded, the number of patients consulting
device clinics has increased each year, extending the wait times at
the clinic.
Remote monitoring (RM) systems for cardiac-implanted
devices that transmit data from the implanted device from
remote locations to the medical institution through analog or
wireless telephones have recently been introduced in Japan. The
transmitters are able to interrogate the device, either manually by
the patient’s use of a telemetry wand or automatically using
wireless technology [2].rt Rhythm Society. Published by E
: þ81 6 6646 6808.
.jp (M. Takagi).RM systems consist of data acquisition by the device on a
scheduled basis followed by transmission of predeﬁned alerts to
the physician as necessary [1]. RM has been widely used in the
U.S. and in European countries. Recent studies from these coun-
tries have demonstrated positive effects of RM [3–6], but the
beneﬁts of RM have not been fully evaluated in Japan. The
objective of the present study was to investigate the clinical
beneﬁts of RM, particularly with respect to outpatient wait times
and times to detection of EVENTS that we deﬁned sustained
ventricular tachyarrhythmic events, worsening heart failure, and
inappropriate therapy for supraventricular tachyarrhythmias
(SVT), in a single center in Japan.2. Methods
2.1. Patients
This study was designed as a prospective evaluation of RM in
patients with cardiac-implanted devices. All of the patients in the
study population had had pacemakers, implantable cardioverter-
deﬁbrillators (ICD), or cardiac resynchronization therapy with
deﬁbrillators (CRT-D) implanted at our institution. Patientslsevier B.V. All rights reserved.
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RM) group. Either the CareLink system (Medtronic, Inc., Minnea-
polis, MN, USA; for pacemakers, ICDs, and CRT-Ds) or the
Merlin.net system (St. Jude Medical, Inc., St. Paul, MN, USA; for
ICDs and CRT-Ds) was used in RM patients. The 2 RM systems are
compared in Table 1. The RM system was explained to all patients
using newly implanted or generator-exchanged ICDs or pace-
makers from Medtronic or St. Jude Medical. Patients from whom
written informed consent could be obtained were enrolled in the
RM group, while other patients with ICDs and pacemakers were
assigned to the non-RM group.
The physician decided whether each patient was assigned to
the CareLink system or Merlin.net system based on the patient’s
medical condition. The patients with history of congestive heart
failure were generally given Medtronic devices due to the avail-
ability of OptiVol Monitoring. OptiVol Fluid Status Monitoring,
which is available only in the CareLink system, measures the
intrathoracic impedance between the implanted lead in the right
ventricle (RV) and the device generator and provides early
detection of worsening heart failure [7–9].
This study was approved by the ethics committees of Osaka
City University. A written informed consent to participate was
obtained from all patients.Table 2
Event trigger settings (CareLink system).
Electrical reset Active can off
Excessive charge time End of Service OptiVol index 460
Charge circuit timeout (30 seconds) RV lead integrity
VF detection/therapy off RV lead noise
RV pacing impedance o200 O, 42500 O ERI
RV deﬁbrillation impedance o20 O, 4200 O RA pacing impedance
o200 O, 42500 O
SVC deﬁbrillation impedance o20 O,
4200 O
LV pacing impedance
o200 O, 42500 O
All therapies in a zone exhausted Number of shocks delivered in
an episode
Pacing mode DOO, VOO or AOO AT/AF daily burden 46 hours
Average ventricular rate during AT/AF
4100 bpm (46 hours)
VF: ventricular ﬁbrillation, RV: right ventricle, AT: atrial tachycardia, SVC: superior
vena cava, LV: left ventricle, RA: right atrium, ERI: elective replacement indicator,
AF: atrial ﬁbrillation, bpm: beats per minute.2.2. Evaluation
The outpatient wait times and times to notiﬁcation of EVENTS
were compared between RM and non-RM patients. At our
institution, patients with cardiac devices undergo medical exam-
inations after their devices have been checked in another room.
However, the patients using the CareLink system can skip the
device check. Outpatient wait time was deﬁned as the interval
from the time of the appointment for the device check to the start
of the medical examination.
The time to EVENTS notiﬁcation was deﬁned as the time from
the onset of the EVENTS to the notiﬁcation of the physician. The
rates of EVENTS and emergency visits and data conﬁrmation
times (device check time or RM data conﬁrmation time) were
also compared between the RM and the non-RM groups. The
precise day and time at which the alert events occurred could be
identiﬁed only for EVENTS (alert events due to increased OptiVol
index, shock therapy, or ATP [anti-tachycardia pacing] delivered
for sustained VT or VF, including inappropriate therapy). There-
fore, the times to notiﬁcation of the EVENTS were evaluated and
compared between the RM and non-RM groups. Patients wereTable 1
Comparison of the RM systems.
CareLink system (Medtronic, I
Device pacemakers, ICD, CRT-D
Characteristic stationary
Data transmission analog phone line
Transmission range 3 m
Home telemetry pacemakers: wand ICD, CRT-D:
Frequency of transmissions scheduled follow-up, alert even
Scheduled follow-up at 3:00 a.m.
Response to events immediate transmission
Retransmission every 3 h for 3 days
Physician notiﬁcation SMS, e-mail, smartphone
IEGM (arrhythmic episodes) all recorded episodes
Special features automatic RA, RV and LV pacing
OptiVol Fluid Status Monitoring
SMS: short message service, IEGM: intracardiac electrocardiogram, RA: right atrium.
RV: right ventricle, LV: left ventricle.
a Except for the ﬁrst transmission using wand-operated transmitters.diagnosed with worsening heart failure based on their general
conditions, including symptoms, chest radiography ﬁndings,
blood test parameters, and OptiVol ﬁndings (OptiVol index 460
(ohm-days)).
The device check time in non-RM patients was deﬁned as the
interval from the interrogation of the implanted device using the
programmer to the printing of all of the data at the clinic. The RM
data conﬁrmation time was deﬁned as the interval from clicking
on the web site to transmit the data to the printing of the data at
the clinic. The transmitted alert data were checked at the clinic
every weekday at 9 a.m., while the scheduled transmitted data
were checked at the clinic a day before each scheduled visit.
2.3. Patient follow-up and data collection
Patients with pacemakers: both RM and non-RM patients were
followed up at ofﬁce visits every 6 months. The RM patients’
device data were transmitted every 6 months on a scheduled
basis.
Patients with ICDs or CRT-Ds: both RM and non-RM patients
were followed up at ofﬁce visits every 3 months. The RM patients’
device data were transmitted every 3 months on a scheduled
basis.
In addition, the contents of any inquiries to the RM call center
for troubleshooting of the RM system and of the alert data were
evaluated during the follow-up examinations of RM patients. The
alert settings of the RM group are shown in Tables 2 and 3.nc.) Merlin.net system (St. Jude Medical, Inc.)
ICD, CRT-D
stationary
wireless, analog phone line
3 m
Wirelessa wireless
ts scheduled follow-up, alert events
between 2 a.m. and 4 a.m.
immediate transmission
every 2 h for 24 h
fax, e-mail, SMS text, smartphone
all recorded episodes
thresholds alerts fully conﬁgurable online
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Outpatient wait times and times to notiﬁcation of EVENTS
were compared between the RM and the non-RM groups using a
Student’s t-test or Aspin-Welch t-test. All data are shown as the
mean7standard deviation. P-values less than 0.05 were consid-
ered signiﬁcant. All events from the day after enrollment to
patient death were included.3. Results
3.1. Patient characteristics
A total of 416 patients (66 in the RM group and 350 in the non-
RM group) were enrolled from November 2009 to September
2011. However, 5 patients in the RM group were excluded because
they lacked access to an analog telephone (n¼2), were unwilling
to conduct CareLink or Merlin.net follow-up visits (n¼2), or were
found to have dementia (n¼1). These 5 patients were reassigned
to the non-RM group. Therefore, the ﬁnal data evaluated came
from 61 patients in the RM group and 355 in the non-RM group.
The numbers of patients with pacemakers, ICDs, and CRT-Ds wereTable 3
Event trigger settings (Merlin.net system).
ST episode detected RA pacing lead impedance out of range
Tachycardia therapy disabled RV percent pacing greater than limit
Device programed to emergency
pacing
LV pacing lead impedance out of range
Charge time limit reached AT/AF episode duration 4threshold
Possible HV circuit damage AT/AF burden 4threshold
Longevity analysis Average RV rate during AT/AF
4threshold
Device reset HV therapy delivered
Back-up VVI mode Successful ATP pacing delivered
Device at ERI Therapy accelerated rhythm
Device at end of service RV pacing lead impedance out of range
Possible HV lead issue BiV percent pacing less than limit
HV pacing lead impedance out of
range
Episode with alert conditions
HV: high voltage, ATP: anti-tachycardia pacing, BiV: biventricular.
Table 4
Patient characteristics.
(a) PM RM (n¼18)
Age 65.3711.4
Male 6 (33%)
Heart disease SSS 7 (39%)
AV block 11 (61%)
(b) ICD/CRT-D RM (n¼43)
Age 62.0714.4
Male 38 (88.3%)
LVEF (%) 42.8715.6
CareLink (n¼23)
OMI 4
DCM 5
HCM 6
ARVC 0
Heart disease Sarcoidosis 1
Brugada 4
LQT 0
IVF/IVT 3
Valuvlar disease 0
HHD 0
OMI: old myocardial infarction, LQT: long QT syndrome, DCM: dilated cardiomyopathy
ARVC: arrhythmogenic right ventricular cardiomyopathy, IVF: idiopathic ventricular ﬁ
HHD: hypertensive heart disease.256, 140, and 20, respectively. A total of 1,460 visits for the non-
RM group and 125 visits for the RM group were analyzed, with an
average number of visits per patient of 372 (range, 1 to 10 visits)
over a mean follow-up period of 41979 days (range, 6 to 698
day). The mean age of all patients at the time of implantation was
69.7713.7 years, and 239 (57%) were male. The characteristics of
the patients in this study are shown in Table 4. The patients with
pacemakers were younger in the RM group than in the non-RM
group, while the characteristics of patients with ICDs or CRT-Ds
were similar between the RM and non-RM groups. The 41 patients
in the RM group using the CareLink system were younger than the
189 patients in the non-RM group using Medtronic devices. The
patients in the RM group using the CareLink system and the
Merlin.net system had similar characteristics.
3.2. Scheduled data transmission in RM patients
In total, 125 scheduled data transmissions were performed
successfully; these consisted of 22, 79, and 24 data transmissions
in patients with pacemakers, ICDs, and CRT-Ds, respectively.
Eighty-seven data transmissions using the CareLink system and
38 data transmissions using the Merlin.net system were analyzed.
The 125 scheduled transmissions during the mean follow-up
period of 360722 days in the RM group contained the following
15 alert events (12%): 14 incidents of sustained ventricular
tachycardia (VT) and 1 of ventricular ﬁbrillation (VF). All of the
15 alert events were EVENTS. The average number of EVENTS per
transmission with alert events was 0.1 (0–8 EVENTS).
All of the 14 VT EVENTS were treated by ATP therapy in
patients with the CareLink system. However, these events were
included in scheduled transmissions rather than transmitted as
unscheduled alerts because it was impossible to set ATP therapy
for VT as an alert event in the CareLink system.
The 1 VF event in the scheduled transmissions from the
CareLink system involved shock delivery to treat the VF. This
did not triggered an alert event even though the alert was
triggered for EVENTS because the CareLink system does not
trigger again until it is reset by an in-ofﬁce interrogation [10].
The automatic transmissions of 8 events by the CareLink
system were unsuccessful because the transmitter was not set
up and initiated to send out transmissions (n¼3), inappropriatenon RM (n¼238) P value
75.0711.6 0.0005
102 (43%) 0.05
111 (47%) 0.58
127 (53%) 0.51
non RM (n¼117) P value
62.2712.6 0.91
93 (79.4%) 0.15
43.0716.2 0.94
Merlin.net (n¼20) non RM (n¼117)
9 36 0.56
2 15 0.37
2 12 0.13
1 3 0.71
1 6 0.77
1 29 0.05
0 1 0.60
2 8 0.41
2 5 0.74
0 2 0.53
, HCM: hypertrophic cardiomyopathy.
brillation, IVT: idiopathic ventricular tachycardia.
Table 5
Troubleshooting calls.
CareLink Merlin.net
Transmission 8 6
Conﬁrmation of data arrival 9 0
Transmitter setting 8 0
Others 4 0
Total 29 6
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transmitter (n¼3), the transmitter was disconnected from the
analog phone line (n¼1), or technical problems occurred with the
telephone line (the analog telephone line was too old to transmit)
(n¼1). The automatic transmissions of 8 events by the Merlin.net
system were unsuccessful because inappropriate circumstances
occurred in which the patient was away from the transmitter
(n¼1), a cellular adapter card did not ﬁt in the transmitter (n¼1),
or technical errors occurred (the capacity of the data commu-
nication card was exceeded) (n¼6).
The contents of the troubleshooting calls are shown in Table 5.
Eight calls for the CareLink system and 4 calls for the Merlin.net
system were requests for physicians to set the transmitters.
3.3. Unscheduled transmitted alert data for RM patients during
the follow-up period
A total of 65 unscheduled transmissions were successfully
transmitted; 46 and 19 transmissions occurred in patients with
ICD and CRT-D, respectively.
The 65 unscheduled transmissions that occurred during the
follow-up period contained 202 alert events. The average number
of alert events per transmission was 3.1 (1–13 events). The
contents of the alert events were as follows: OptiVol ﬂuid index
exceeding the threshold in the CareLink system (n¼25), VT
(n¼114), VF (n¼6), atrial ﬁbrillation (AF) burden (n¼16), AF
episode of long duration (n¼15), ventricular high rate during AF
(n¼8), ventricular pacing rate in CRT-D less than 90% (n¼5),
ventricular pacing rate in ICD over 40% (n¼2), signiﬁcant ST
deviation (n¼2), and inappropriate therapy for SVT (n¼9; 2 sinus
tachycardia, 5 AF, and 2 atrial tachycardia events).
The 202 alert events contained the following 62 EVENTS:
OptiVol ﬂuid index over threshold (n¼25), VT (n¼22), VF
(n¼6), and inappropriate therapy for SVT (n¼9). The average
number of EVENTS per transmission with alert events was 0.95
(0–13 EVENTS). Transmission of alerts prompted unscheduled
contacts performed by phone. These phone calls resulted in 15
unscheduled ofﬁce visits for the following reasons: OptiVol ﬂuid
index exceeding the threshold (n¼7), delivered shock (n¼7), and
ventricular pace rate in CRT-D less than 90% (n¼1). Of the 15
unscheduled visits, 5 determined that reprogramming of the
device was required and 3 that hospitalization was needed.
3.4. Alert events in non-RM patients
At the clinic, we found the following 376 alert events in non-
RM patients during the mean follow-up period of 429710 days:
OptiVol ﬂuid index exceeding the threshold according to the
Medtronic device (n¼101), VT (n¼141), VF (n¼20), device at
Elective replacement indicator (n¼18), RV lead noise (n¼2), right
atrium (RA) pacing lead impedance out of range (n¼2), possible
high-voltage lead issue (n¼2), ventricular pace rate in ICD over
40% (n¼43), and ventricular pace rate in CRT-D less than 90%
(n¼3). Inappropriate therapy for SVT was included in the follow-
ing 44 alert events (12%): sinus tachycardia (n¼18), AF (n¼21),and atrial tachycardia (n¼5). The 376 alert events included 306
EVENTS. These were OptiVol ﬂuid index over the threshold
(n¼101), VT (n¼141), VF (n¼20), and inappropriate therapy for
SVT (n¼44).
Sixty-eight unscheduled visits were made by patients in the
non-RM group during the follow-up period because of heart failure
(n¼43), delivered shock (n¼8), palpitation (n¼12), syncope
(n¼3), and alert sound from the device (n¼2). Reprogramming
of the device was needed at 9 visits, and hospitalization was
needed at 26 visits. The rate of hospitalization was signiﬁcantly
higher at the unscheduled visits (38%) than at the scheduled visits
(5 visits, 0.003%) (Po0.001).3.5. Outpatient wait times
The outpatient wait times at the clinic were 17.6722.1 min
for the RM group and 35.6725.2 min for the non-RM group in all
patients (Po0.001), 6.6723.6 min for the RM group and
32.6722.0 min for the non-RM group for patients with pace-
makers (Po0.001), and 19.4725.6 min for the RM group and
41.2725.5 min for the non-RM group for patients with ICDs or
CRT-Ds (Po0.001) (Fig. 1). For patients with Medtronic ICDs or
CRT-Ds, the outpatient wait times were signiﬁcantly shorter for
the RM group (14.2720.9 min, n¼44) than for the non-RM group
(42.7724.5 min, n¼162) (Po0.001). However, for patients with
St. Jude Medical ICDs or CRT-Ds, the outpatient wait time did not
differ signiﬁcantly between the RM group (28.7713.0 min,
n¼20) and the non-RM group (38.1727.9 min, n¼70) (P¼
0.14). The wait time was signiﬁcantly shorter for patients using
the CareLink system than for patients using the Merlin.net system
(Po0.001).3.6. Data conﬁrmation time
The average device check time at the outpatient clinic was
4.973.2 min at scheduled visits (n¼1,460). The RM data con-
ﬁrmation time per patient was 4.372.9 min (n¼125). The RM
data conﬁrmation time was signiﬁcantly shorter than the device
check time at the outpatient clinic (Po0.001).3.7. Time to notiﬁcation of EVENTS
The study included 383 EVENTS (77 in the RM group and 306
in the non-RM group). The average time to notiﬁcation of EVENTS
was 8.1716.2 days for the RM group and 38.7733.2 days for the
non-RM group (Po0.001). The time to notiﬁcation was
14.3720.8 days for patients using the CareLink system (n¼42)
and 2.171.3 days for patients using the Merlin.net system
(n¼35). The time to notiﬁcation was signiﬁcantly shorter for
patients using the Merlin.net system than for patients using the
CareLink system (Po0.001). The time to notiﬁcation of sustained
ventricular tachyarrhythmias was 26.6723.1 days for patients
using the CareLink system (n¼21) and 2.571.2 days for patients
using the Merlin.net system (n¼22) (Po0.001). However, when
we excluded ATP therapy in patients using the CareLink system
from the EVENTS, the time to notiﬁcation of EVENTS was 1.170.4
days for patients using the CareLink system (n¼27). Therefore,
the difference in time to notiﬁcation of EVENTS between the
2 systems is due mainly to the inability of the CareLink system to
transmit ATP therapy for VT as an alert.
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4.1. Main study ﬁndings
This study revealed that the use of RM signiﬁcantly shortened
outpatient wait times, times to notiﬁcation of EVENTS, and data
conﬁrmation times at the clinic in patients with implanted
cardiac devices at a single Japanese center. The monitoring of
implanted cardiac devices through RM technology may provide
beneﬁts for the clinical management of patients in Japan.
4.2. Scheduled data transmission in RM patients
In the RM patients, 125 scheduled data transmissions (89%)
were performed successfully. This result conﬁrms the previously
reported feasibility, reliability, and availability of RM of implanted
devices in most cases [11,12]. Of the remaining 16 scheduled data
transmissions (11%) that were not transmitted, 8 data transmis-
sions by the CareLink system were not successfully transmitted
because the transmitter was not set up and initiated to send out
transmissions or inappropriate circumstances occurred in which
the patient was away from the transmitter, the transmitter was
not connected to an analog phone line, or technical problems
occurred with the phone line. These reasons for unsuccessful
transmission by the CareLink system were similar to those in a
previous report from the U.S. and European countries [10]. In a
Japanese multicenter study, Ando et al. reported that a total of
470 transmissions were attempted, of which 385 (81.9%) were
successful [13]. Although the proportion of patients with pace-
makers who had to transmit data by wand-operated transmission
was higher in their study (53.2%) than in ours (36.1%), the rates of
successful transmissions were similar. Eight data transmissions
by the Merlin.net system were not successfully transmitted
because inappropriate circumstances occurred in which the
patient was away from the transmitter, a cellular adapter card
did not ﬁt in the transmitter, or technical errors occurred (thecapacity of the data communication card was exceeded). Such
technical errors associated with the Merlin.net system were
peculiar to Japan and were due to the unstable mobile phone
signals and the small number of mobile phone operating stations
in Japan.
Twenty-ﬁve of the 125 transmissions (20%) required outside
assistance. Schoenfeld et al. reported that patients did not require
outside assistance in 91% of 110 transmissions and that 93% of
second transmissions were unassisted [14]. In our study, the rate
of outside assistance was slightly higher than previously reported.
However, most of the requests for outside assistance were only
for conﬁrmation of transmission despite the successful transmis-
sion of all data.
4.3. Unscheduled transmitted alert data in RM patients during
the follow-up period
Lazarus et al. reported that most of the alert data transmitted
by RM were related to heart failure, progression of AF, or ICD
treatment for VF. In our study, 92% of the alert events in RM
patients were related to signs of heart failure, AF, or shocks
delivered for treatment of VT or VF, much as in a previous report
[15]. Most of the alert events (128 events, 59%) in the RM group in
our study were related to VT. After phone calls, 7 unscheduled
visits were made because the physicians judged that examina-
tions at the clinic were warranted, as an increase in the OptiVol
ﬂuid index over the threshold is indicative of heart failure. Of
these 7 patients, 1 was emergently admitted. RM thus enabled the
early detection and treatment of heart failure, AF, VT or VF events,
and inappropriate shock treatment for VT or VF.
4.4. Alert events in non-RM patients
Of the 376 alert events in our non-RM patients, we found 306
EVENTS (81.4%). Sixty-eight unscheduled visits were made due to
the patients’ symptoms. Unfortunately, the rate of hospitalization
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et al. reported that only 34% of complications related to cardiac
implanted devices were detected during routine follow-up [16].
The use of RM in these non-RM patients might have called
attention to events before the patients became symptomatic
and could have reduced the rate of hospitalization.
4.5. Outpatient wait times
The outpatient wait times were signiﬁcantly shorter for the
RM group than for the non-RM group. However, the wait times for
patients using the Merlin.net system did not differ signiﬁcantly
from those of the non-RM group. As the Merlin.net system used
did not have an automatic threshold-measurement function, it
was necessary to check the pacing threshold at the outpatient
clinic. We considered this to be a reason for the lack of signiﬁcant
difference between the RM and non-RM groups for patients using
the Merlin.net system. Use of the latest model (not currently
available in Japan) in which the threshold measurement and
adjustment are performed automatically [17] might result in
shorter outpatient wait times even for the Merlin.net system. In
this study, the outpatient wait time for the RM group was
17.6722.1 min. The outpatient wait time did not include the
time required to travel to and from the clinic or for the actual
medical procedure. Some of our patients required prescriptions
and/or other examinations, such as chest radiographs or blood
examinations, at their follow-up ofﬁce visits. The actual medical
procedure times may have been prolonged for these patients.
Therefore, we evaluated only the actual time spent waiting in
this study.
4.6. Data conﬁrmation time
In our study, the RM data conﬁrmation time (4.372.9 min per
patient) was shorter than the device check time at the outpatient
clinic, as was shown in previous reports [13,17]. In our study, the
RM data conﬁrmation time was deﬁned as the time from clicking
on the web site to transmit data to the printing of the data. Ando
et al. reported that physicians spent an average of 6.475.1 min to
evaluate the data over the internet [13], while Raatikainen et al.
reported that physicians required 8.474.5 min to review device
data on the secure website [17]. Although the RM data conﬁrma-
tion time depends on the performance of the computer, internet
speed, and personal analytical ability, which follows a learning
curve [12], the RM data conﬁrmation time was shorter in this
study than in the previous studies.
4.7. The time to notiﬁcation of EVENTS
In this study, the time to notiﬁcation of EVENTS was signiﬁ-
cantly shorter in the RM group than in the non-RM group. The
clinical beneﬁts of RM for the early detection and treatment of
heart failure, VT or VF events, and inappropriate therapy for VT or
VF were clearly evident. Such monitoring and notiﬁcation can
enable more rapid adjustment of therapy that would otherwise be
delayed until the next scheduled follow-up visit, as previously
reported [18].
The time to notiﬁcation was signiﬁcantly shorter for patients
using the Merlin.net system (2.171.3 days) than for those using
the CareLink system (14.3720.8 days). Once alert data were
transmitted by the CareLink system, the next similar alert data
were not transmitted until the system was reset by in-ofﬁce
interrogation at the clinic. Moreover, the CareLink system did not
transmit ATP therapy for VT as an alert. We speculate that these
defects in the CareLink system were responsible for the different
times to notiﬁcation of the 2 systems. Crossley et al. reported thatthe median time per patient from the occurrence of an event to a
clinical decision was 4.6 days in RM patients using the CareLink
system and 22 days in non-RM patients [10]. Both intervals were
shorter than those in this study. Notably, Crossley et al. did not
include incidents of ATP therapy for VT as EVENTS; we, however,
included the administration of ATP for VT, which was commu-
nicated only at the follow-up ofﬁce visits. This difference probably
explains why the time to notiﬁcation in patients using the
CareLink system was longer in this study than in that of
Crossley et al.
4.8. Limitations
In this study, the outpatient wait time was deﬁned as the
interval from the time of the appointment for the device check to
the start of the medical examination. This time may be inﬂuenced
by the device check time and by the number of patients with
appointments for medical examinations. The device check time
may be affected by the number and severity of alert events
relayed at that time. The RM conﬁrmation time may be affected
by the performance of the computer, internet speed, and personal
analytical ability. These factors may not have been uniform in our
study. We checked all of the alert data from 9 a.m. through 5 p.m.
on weekdays. Therefore, the time to notiﬁcation of EVENTS may
have been longer when the EVENTS occurred on weekends or
holidays. Moreover, we could not evaluate the times to notiﬁca-
tion for alert events other than EVENTS because the date and time
of onset were unclear. This study also included a relatively small
number of patients in the RM group, especially those using the
Merlin.net system.5. Conclusions
The use of RM signiﬁcantly shortened outpatient wait times
and times to notiﬁcation of EVENTS. Early detection and treat-
ment of arrhythmia events, worsening heart failure, and abnor-
mal device performance were possible. The clinical beneﬁts of RM
were evident at a single center in Japan. Further prospective
randomized studies may be needed to identify the patients who
would beneﬁt most from RM of cardiac-implanted devices
in Japan.Conﬂict of interest statement
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